1
|
Nazzani S, Catanzaro M, Macchi A, Torelli T, Stagni S, Biasoni D, Lorusso V, Darisi R, Lanocita R, Cascella T, Maccauro M, Lorenzoni A, Cattaneo L, Montanari E, Salvioni R, Nicolai N. Bilateral inguinal lymph-node dissection versus unilateral inguinal lymph-node dissection and contralateral dynamic sentinel node biopsy in clinical N1 squamous cell carcinoma of the penis. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01215-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
2
|
Fioretti A, Leopizzi T, Giotta F, Lorusso V, Luzzi G, Oliva S. PO-38: A new armamentarium choice in cancer-associated upper-limb vein thrombosis resistant to heparin: a clinical case of seminoma in BEP chemotherapy protocol solved with edoxaban. Thromb Res 2022. [DOI: 10.1016/s0049-3848(22)00228-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Pignot G, Lorusso V, Doisy L, Pacchetti A, Lannes F, Sypre D, Branger N, Maubon T, Rybikowski S, Walz J, Gravis G. Résultats oncologiques à 2 ans de la thermo-chimiothérapie par HIVEC pour tumeurs de vessie réfractaires au BCG. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Pignot G, Lorusso V, Le Quellec A, Pacchetti A, Rion C, Branger N, Maubon T, Rybikowski S, Sypre D, Lannes F, Musi G, Montanari E, De Cobelli O, Walz J. Robot-assisted Diverticulectomy for an early-stage squamous cell carcinoma of the bladder. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)02298-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
5
|
Pacchetti A, Pignot G, Le Quellec A, Maubon T, Branger N, Rybikowski S, Lannes F, Sypre D, Fakhfakh S, Rion C, Lorusso V, Terrone C, Walz J. Pelvectomie antérieure robot-assistée avec préservation sexuelle. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Lorusso V, Doisy L, Pacchetti A, Rybikowski S, Maubon T, Branger N, Lannes F, Sypre D, Fakhfakh S, Gravis G, Walz J, Pignot G. La résection trans-urétrale de vessie de réévaluation est-elle toujours nécessaire en cas de primo-résection sous luminofluorescence par hexaminolévulinate ? Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Luzzago S, Mistretta F, Piccinelli M, Lorusso V, Morelli M, Bianchi R, Catellani M, Cozzi G, Di Trapani E, Pricolo P, Alessi S, Ferro M, Matei D, Petralia G, Musi G, de Cobelli O. MRI-Targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: Follow-up of a precision trial-like retrospective cohort. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35373-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Mistretta F, Ruvolo C, Luzzago S, Piccinelli M, Lorusso V, Morelli M, Bianchi R, Catellani M, Cozzi G, Di Trapani E, Ferro M, Matei D, Musi G, de Cobelli O. Robot-assisted radical cystectomy for bladder cancer: a comparison between intracorporeal vs. extracorporeal orthotopic neobladder. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35614-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Mistretta F, D’Anna G, Luzzago S, Morelli M, Piccinelli M, Lorusso V, Serino A, Cordima G, Brescia A, Cioffi A, Bottero D, Ferro M, Matei D, Musi G, de Cobelli O. Prognostic role of preoperative neutrophil-to-lymphocyte ratio in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35603-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
10
|
Palmisano F, Montanari E, Boeri L, Lorusso V, Ievoli R, Gadda F, Spinelli M, De Lorenzis E, Dell’orto P, Morelli M, Longo F, Serrago M, Ruiz-Castañé E, Albo G, Sánchez-Curbelo J, Sarquella-Geli J. Ten-year experience with prosthetic surgery in the management of erectile dysfunction: Outcomes from a tertiary referral centre and early prosthetic infection predictors. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33087-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
11
|
Albo G, Lorusso V, Palmisano F, Morelli M, Turetti M, Zanetti S, Boeri L, Gallioli A, Sampogna G, Fontana M, De Lorenzis E, Spinelli M, Longo F, Dell'orto P, Montanari E. Robot-assisted pyelolithotomy in a horseshoe kidney. ACTA ACUST UNITED AC 2019. [DOI: 10.1016/s1569-9056(19)32806-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Drago A, Carbone M, Lorusso V, Moschetta M, Scardapane A, Lucarelli N, Angelelli G, Stabile Ianora AA. Amyand's hernia: role of CT for a correct diagnosis. G Chir 2019; 40:44-48. [PMID: 30771798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Amyand's hernia consists in the protrusion of the vermiform appendix into an inguinal hernia sac and represents an uncommon condition with a difficult preoperative diagnosis to be recognized with clinical examination and imaging diagnostic tools in order to choose a correct therapeutic approach for the patient. Four types of Amyand's hernias exist. The case of a recurrent type 1 Amyand's hernia is presented. Multi detector computed tomography allowed a correct diagnosis and the subsequent surgical treatment had no complication for the patient. Radiologists and surgeons need to be aware of this pathology and its classification, as well as of the importance of recognizing both the inflamed and normal appendix within the inguinal canal and the abdominal complications. With the availability of multi detector CT scanning, a greater number of type 1 and 2 hernias are able to be preoperatively diagnosed, and type 3 and 4 better characterized in emergency situation, allowing to perform the best surgical treatment and reducing the chances of pathological recurrence.
Collapse
|
13
|
Lorusso V, Berardi F, Brandi M, Mastria A, Paradiso A, Catino AM, Tatulli C, De Lena M. M-Veca (Methotrexate, Vinblastine, Epidoxorubicin and Carboplatin) in the Treatment of Advanced Urothelial Carcinoma. Tumori 2018; 79:191-4. [PMID: 8236502 DOI: 10.1177/030089169307900306] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background Urothelial cancer is a chemosensitive disease. However, cisplatin or anthracycline-containing regimens still provoke severe toxicity mainly due to reduced renal function and poor performance status (PS) of patients. The aim of this study was to verify the possibility of substituting carboplatin for cisplatin and epirublcin for doxorubicin in the M-VAC regimen in order to reduce toxicity and improve patient tolerance. Methods Twenty patients with advanced urothelial tract tumors were treated with a chemotherapeutic regimen composed of methotrexate (30 mg/mq iv on days 1, 15, 22), vinblastine (3 mg/m2 iv on days 2, 15, 22), epidoxorubicin (35 mg/m2 iv on day 2) and carboplatin (250 mg/m2 iv on day 2) every four weeks (M-VECA). All patients had bidimensionally measurable disease. Results Of the 18 evaluable patients, 3 (17 %) obtained complete response and 7 (33 %) obtained partial response (50 % overall response). The median duration of response was 50 weeks (range, 28-88+). Grade III-IV toxicity (leukothrombocytopenia and mucositis) was observed in 20 % of cases. Nevertheless, recovery was prompt in all but 2 patients with poor PS who died of nadir sepsis. Conclusions M-VECA was an effective regimen for the treatment of patients with metastatic urothelial tumors and was safely employed in patients with a good PS. However, the possibility of substituting carboplatin for cisplatin as neoadjuvant therapy for less advanced stages needs further investigation in randomized studies.
Collapse
Affiliation(s)
- V Lorusso
- Medical Oncology Division, Oncology Institute, Bari, Italy
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Guida M, Casamassima A, Abbate I, Paradiso A, Zito A, Marzullo F, Lorusso V, Timurian A, Cramarossa A, De Lena M. Solitary Plasmacytoma of Bone and Extramedullary Plasmacytoma: Two Different Nosological Entities? Tumori 2018; 80:370-7. [PMID: 7839469 DOI: 10.1177/030089169408000512] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background The relationship between solitary plasmacytoma and multiple myeloma is still unclear, but they can be distinguished by their different clinical course. Indicators of disease activity and extension, and of a possible evolution to multiple myeloma, have not been identified as yet. Methods Two cases of solitary plasmacytoma are described: one of the mandible and one extramedullary plasmacytoma (EMP) of the rhinopharynx. Pathologic data included immunohistochemical staining for heavy and light Ig chains, and for the proliferating cell nuclear antigen (PCNA). Analysis of the peripheral immunological status and serum parameters ( β2 microglobulin, thymidine kinase, IL-2, IL-6 and soluble IL-2 receptor) was performed and correlation was made with the clinical status. Flow cytometry analysis of nuclear DNA content and S-phase cell fraction were also studied in both neoplasms. Results Solitary plasmacytoma of bone (SPB) showed important basal immunologic alterations and a marked increase in all serum parameters considered with respect to EMP. Ploidy analysis demonstrated an almost complete aneuploidy cell population for the SPB patient (80%), whereas in the EMP patient only 2% of the cells were aneuploid. The S-phase ceils were 16% and 4%, respectively. PCNA index was 60% in SPB and 10% in EMP. Conclusions Solitary plasmacytoma of the bone appeared to be a more aggressive form of plasmacellular neoplasia, distinct from EMP and similar to multiple myeloma. The study of serum parameters, together with analysis of PCNA, ploidy and S-phase fraction, can aid in better understanding disease activity, and in the choice of more adequate treatment. Moreover, serial analysis of some serum factors might be useful markers for monitoring the disease.
Collapse
Affiliation(s)
- M Guida
- Medical Oncology Division, Oncology Institute, Bari, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Alaibac M, Paradiso A, Giannella C, Labriola A, Marzullo F, Lorusso V, De Lena M. Immunoglobulin Heavy Chain Gene Rearrangement in B-Cell Non-Hodgkin's Lymphomas Detected by the Polymerase Chain Reaction. Tumori 2018; 81:128-31. [PMID: 7778215 DOI: 10.1177/030089169508100211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background Immunoglobulin heavy chain gene rearrangement serves as a marker of clonality and cell lineage in B-cell lymphoproliferative disorders. In this study we used the polymerase chain reaction (PCR) to detect clonal rearrangements of the immunoglobulin heavy chain gene in a group of patients with B-cell lymphomas. Methods DNA was extracted from frozen tissue of 40 B-cell non-Hodgkin's lymphomas and subjected to PCR amplification using primers that recognize conserved sequences of the variable and joining regions of the immunoglobulin heavy chain gene. Results Monoclonal rearrangements were detected in 23 of 40 malignant B-cell lymphomas. No clonal rearrangements were detected in the 10 control cases. Conclusions We conclude that this PCR-based technique may provide a simplified and rapid approach for the detection of clonal immunoglobulin heavy chain gene rearrangements in B-cell lymphomas without recourse to Southern blotting, which can be reserved for cases in which PCR is negative.
Collapse
Affiliation(s)
- M Alaibac
- Experimental and Clinical Oncology Laboratory, Oncology Institute, Bari, Italy
| | | | | | | | | | | | | |
Collapse
|
16
|
De Lena M, Tommasi S, Schittulli F, Lorusso V, Paradiso A. Sequential Alternate Administration of Tamoxifen and Medroxyprogesterone Acetate in Advanced Breast Cancer: Clinical-Biological Randomized Study. Tumori 2018; 76:190-5. [PMID: 2139523 DOI: 10.1177/030089169007600208] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
From January 1985 to September 1988, 60 women with advanced breast cancer were randomized in two arms to receive: A) tamoxifen (TAM) (20 mg/die) until progression or B) TAM (20 mg/die for 14 days) then medroxyprogesterone acetate (MPA) (1500 mg/die p.o. for 14 days) followed by 7 days of wash-out before repeating the TAM/MPA treatment. All patients were postmenopausal, previously untreated with hormone therapy, and with tumor receptor status determined immediately before randomization; all had objectively evaluable lesions. In order to verify hormone receptor variations due to the antiestrogen, when possible a second biopsy was performed after the initial 14 day cycle of TAM. Thirty-one and 29 patients were included respectively in arms A and B. Objective regression (CR+PR) was observed in 58% of group A and 75% of group B, with CR in 11% and 23%, respectively. Differences were not statistically significant. Median time to progression was 12 months for group A and 9 for group B. Overall survival has not yet been reached in group A while it was 34 months for patients of group B. Metrorrhagia was observed in two cases of group A and in 6 of group B, and thrombophlebitis in 1 and 3 cases, respectively. The second biopsy confirmed a clear increase of PgR content in 8/11 cases (75%). Plasma level variations of TAM, N-desmethyl TAM and MPA were checked at various intervals on 3 patients of group B, and confirmed that our schedule is able to produce a drug wash-out period for tumor cells. In conclusion, our study demonstrated that while the manipulation of hormone receptors seems possible, results indicating better overall survival and time to progression were not obtained with alternate sequential TAM-MPA therapy.
Collapse
Affiliation(s)
- M De Lena
- Oncology Division, Oncology Institute, Bari, Italy
| | | | | | | | | |
Collapse
|
17
|
Comella P, Lorusso V, Casaretti R, De Lucia L, Cartení G, Manzione L, Mancarella S, De Lena M, Comella G. Concurrent Modulation of 5-Fluorouracil with Methotrexate and L-leucovorin: An Effective and Moderately Toxic Regimen for the Treatment of Advanced Colorectal Carcinoma a Multicenter Phase II Study of the Southern Italy Cooperative Oncology Group. Tumori 2018; 85:465-72. [PMID: 10774567 DOI: 10.1177/030089169908500608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and Background Methotrexate (MTX) and leucovorin (LV) can enhance the cytotoxicity of 5-fluorouracil (5FU) by modifying its metabolic pathway inside target cells. Some preclinical studies and clinical trials have suggested that the concurrent or sequential double modulation of 5FU by means of MTX and LV may give a higher activity than single biochemical modulations. The purpose of our phase II study was to assess the activity and toxicity of a biweekly regimen including MTX, levo-LV and 5FU in colorectal cancer patients. Methods From July 1994 to May 1997, 100 consecutive patients affected by advanced or metastatic colorectal carcinoma were given MTX, 750 mg/m2 iv (2-h infusion) on day 1, and levo-LV, 250 mg/m2 iv (2-h infusion) followed by 5FU, 800 mg/m2 iv bolus on day 2, every two weeks. Patients were treated until complete response or progressive disease was documented, or for a maximum of 16 courses. Results Among 97 eligible patients, 5 complete and 25 partial responses were obtained, giving an overall response rate of 31% (95% exact confidence limits, 22-41%). Response rate was significantly higher in patients with a good (ECOG scale 0) than with a poor (ECOG scale 1 or 2) performance status (40% versus 17%, P <0.02). Median time to treatment failure was 27 weeks, median survival time was 63 (95% confidence limits, 54-71) weeks, and 2- and 3-year probability of survival were 34% and 12%, respectively. Performance status was the only pretreatment characteristic significantly affecting the outcome of patients. Indeed, median survival time was 94 weeks for patients with a performance status = 0 and 37 weeks for patients with a performance status ≥ 1 (P < 0.05). Toxicity of the treatment was low and manageable; grade 3 to 4 leukopenia affected 8% of patients, whereas grade 3 diarrhea and mucositis occurred in 5% and 4%, respectively. Conclusions The double biochemical modulation of 5FU by MTX and levo-LV is at least as effective as, and probably more effective than, the single modulation by MTX or by LV. It may therefore represent a therapeutic option for the palliative treatment of patients with advanced colorectal carcinoma.
Collapse
Affiliation(s)
- P Comella
- Division of Medical Oncology A, National Tumor Institute, Naples, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G, Lucarelli C. Measurement of the Ovarian Cancer-Associated Antigen CA 125 in Monitoring Tumor Burden and Response to Chemotherapy. Tumori 2018; 77:167-9. [PMID: 2048231 DOI: 10.1177/030089169107700216] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
CA 125 serum levels were measured in 74 patients with ovarian carcinoma. Among 31 patients undergoing a second look laparotomy (SL) after chemotherapy pathologic complete response (PCR) was observed in 14 patients, residual disease (RD) < 2 cm in 7 patients and RD >2 cm in 10 patients. The disease status was compared to the CA 125 serum levels measured just before SL. Thirteen of the 14 patients with PCR had serum CA 125 values < 35 U/ml (specificity: 93 %). On the other hand, only 10 of the 17 patients with RD showed serum levels > 35 U/ml (sensitivity: 59 %). Moreover, in the 43 patients receiving chemotherapy, CA 125 levels correlated with the course of the disease in 36 (84 %). With regard to early detection of recurrence, in 9/14 patients with PCR, whose CA 125 levels were monitored monthly, by 1 to 7 months an increase of the tumor marker preceded clinical evidence of relapse in 9/9 relapses (100%). In conclusion, CA 125 assay can be helpful in the management of ovarian cancer patients, in monitoring the response to chemotherapy, in the early detection of tumor recurrence, and in predicting the SL findings, although the low sensitivity could be a major drawback in patients with RD before SL.
Collapse
Affiliation(s)
- M Quaranta
- U.O. Laboratorio Analisi, Oncology Institute, Bari, Italy
| | | | | | | | | | | | | |
Collapse
|
19
|
De Lena M, Lorusso V, Iacobellis U, Marzullo F, Maiello E, Cramarossa A. Cis-Diamminedichloroplatinum Activity in Bidimensionally Measurable Metastatic Lesions of Bladder Carcinoma. Tumori 2018; 70:85-8. [PMID: 6538708 DOI: 10.1177/030089168407000114] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Cis-diamminedichloroplatinum (CDDP) was administered i.V., at the dosage of 20 mg/m2 for 5 consecutive days and recycled every 3 weeks, to 11 patients with bidimensionally measurable metastatic lesions from bladder cancer previously untreated with antineoplastic drugs. Eight patients (6 men and 2 women) were evaluated for clinical response and 9 for toxicity. No complete regression was observed, and partial regression was obtained only in 3 patients (37.5 %). Severe leukopenia and thrombocytopenia occurred only occasionally; moderate nausea and vomiting were observed in 5 cases. Nephrotoxicity was noted in 4 of the 9 patients evaluable for toxicity, and 2 of them, with ureteral obstruction, died of renal failure.
Collapse
|
20
|
De Lena M, Brandi M, Logroscino A, Lorusso V, Paradiso A, Maiello E. Intravenous Administration of Cyclophosphamide, Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer. A Pilot Study. Tumori 2018; 74:57-63. [PMID: 3162624 DOI: 10.1177/030089168807400110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Sixty-two women with advanced breast cancer were admitted to a pilot study in which a modified CMF regimen was administered. Cyclophosphamide was administered i.v. at a dosage of 600 mg/m2 on the same day as fluorouracil (600 mg/m2/i.v.) and methotrexate (40 mg/m2/i.v.). The therapy was recycled on the 21st day and in the presence of myelosuppression, the administration of the drugs was delayed for 1-2 weeks recovery of the hematologic values. CR + PR were obtained in 42% of patients and no change in 32% (U.I.C.C. criteria). Metastases to soft tissues showed CR + PR in 55% of the cases, bone in 33% and viscera in 35%. The menopausal status, the disease-free interval and the number of involved sites did not influence statistically the percentage of responses; however, the response rate was influenced statistically by previous treatment. The median duration of response was 7.5 months; the median overall survival of the 60 evaluable patients was 18 months. Due to myelosuppression, CMF i.v. administration was delayed 90/620 times (14%). Toxicity was acceptable and had a lower incidence than that reported in the literature in different series of CMF administered p.o. Nausea and vomiting, in particular, were limited to 24-48 h after administration of the drugs, and alopecia was seldom observed.
Collapse
|
21
|
Russo P, Papa V, Russo S, Bella AD, Pabst G, Milazzo G, Balestrazzi A, Caporossi A, Anselmetti G, Lorenzi U, Orsi R, Faletti P, Bindella G, Boccassini G, Kropp B, Calabria G, Campagna P, Ciurlo C, Caporossi A, Tasciotti A, Licignano R, Balestrazzi A, Caprioglio G, Birattari F, Franch A, Darondeau J, Blanluet G, Ouen S, Guerra R, Saccarola P, Lenz W, Schuff O, Lùpidi G, Coiràn M, Checcucci M, Burattini L, Foligno, Mastropasqua L, Ciancaglini M, Ciafrè M, Cerulli A, Moretti G, Padovano S, Rotondo SG, Neuhann T, Okrafka K, Ratiglia R, Oldani A, Reiss H, Rochefort J, Coulombe B, Sborgia C, Lorusso V, Palmisano C, Moramarco N, Spinelli D, Curatola M, Maruccia A, Vaona P, Faraldi F, Villani C, Schiavone M, Gisoldi RC. Topical Nonsteroidal Anti-Inflammatory Drugs in Uncomplicated Cataract Surgery: Effect of Sodium Naproxen. Eur J Ophthalmol 2018. [DOI: 10.1177/112067210501500510] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To investigate whether topical nonsteroidal anti inflammatory drugs (NSAIDs) are useful, in the absence of concomitant corticosteroid therapy, in limiting postoperative inflammation after uncomplicated cataract surgery. Methods A total of 328 patients were enrolled in a prospective, randomized, double-masked, parallel-group, active-controlled study. Anterior chamber inflammation (ACI) was evaluated as the primary efficacy parameter. Only patients with moderate inflammation (ACI score of ≤4) the day after surgery were randomized and treated with NSAIDs. A novel topical formulation containing 0.2% sodium naproxen was compared with 0.1% diclofenac. Both were administered three times a day for 14 consecutive days. Ocular inflammation was measured after 7 and 14 days by using slit-lamp biomicroscopy. Safety parameters were also evaluated at the same time. Results Both treatments were equally effective in controlling postsurgical inflammation. No statistically significant differences between treatment groups were observed for the safety variables. No serious adverse events (AEs) occurred during the course of the study. The most frequent AE reported with naproxen was eye redness. Conclusions NSAIDs can effectively be used without concurrent administration of corticosteroids to control postoperative inflammation after uncomplicated cataract surgery. In addition, naproxen ophthalmic solution may be considered a suitable alternative to the currently available NSAIDs.
Collapse
Affiliation(s)
- P. Russo
- Medical Department SIFI SpA, Catania - Italy
| | - V. Papa
- Medical Department SIFI SpA, Catania - Italy
| | - S. Russo
- Medical Department SIFI SpA, Catania - Italy
| | - A. Dl Bella
- Medical Department SIFI SpA, Catania - Italy
| | - G. Pabst
- AAI Deutschland GmbH & Co KG, Neu-Ulm - Germany
| | - G. Milazzo
- Medical Department SIFI SpA, Catania - Italy
| | - A. Balestrazzi
- Department of Ophthalmology, University of Siena, Siena - Italy
| | - A. Caporossi
- Department of Ophthalmology, University of Siena, Siena - Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vischi A, Guerriero S, Giancipoli G, Lorusso V, Sborgia G. Delayed Onset of Pseudotumor Cerebri Syndrome 7 Years after Starting Human Recombinant Growth Hormone Treatment. Eur J Ophthalmol 2018; 16:178-80. [PMID: 16496267 DOI: 10.1177/112067210601600131] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Purpose To report a case of pseudotumor cerebri (PTC) following treatment with human recombinant growth hormone (GH). Methods A 42-year-old man who developed pseudotumor cerebri 7 years after starting human recombinant GH treatment is presented. Results The patient's medical history was significant for hypophyseal dwarfism with a serious deficit of GH, hypogonadotropic hypogonadism, and hypothyroidism. In 1996 he started taking GH, testosterone, and l-thyroxine. Fundus examination showed disc edema in the left eye. GH was discontinued, and acetazolamide therapy was initiated. At the 3-month follow-up the acuity without correction was patch and the unilateral papilledema had resolved. Conclusions Pseudotumor cerebri or idiopathic intracranial hypertension is an uncommon and complex disorder. The diagnosis is possible when important criteria symptoms and signs are met. Several conditions and risk factors are associated with PTC. The most recently recognized risk factor is GH therapy.
Collapse
Affiliation(s)
- A Vischi
- Department of Ophthalmology, Division of Ophthalmology, University of Bari, Italy.
| | | | | | | | | |
Collapse
|
23
|
Caruso G, Bonomo M, Valpiani G, Salvatori G, Gildone A, Lorusso V, Massari L. A six-year retrospective analysis of cut-out risk predictors in cephalomedullary nailing for pertrochanteric fractures: Can the tip-apex distance (TAD) still be considered the best parameter? Bone Joint Res 2017; 6:481-488. [PMID: 28790037 PMCID: PMC5579311 DOI: 10.1302/2046-3758.68.bjr-2016-0299.r1] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Accepted: 05/10/2017] [Indexed: 11/05/2022] Open
Abstract
Objectives Intramedullary fixation is considered the most stable treatment for pertrochanteric fractures of the proximal femur and cut-out is one of the most frequent mechanical complications. In order to determine the role of clinical variables and radiological parameters in predicting the risk of this complication, we analysed the data pertaining to a group of patients recruited over the course of six years. Methods A total of 571 patients were included in this study, which analysed the incidence of cut-out in relation to several clinical variables: age; gender; the AO Foundation and Orthopaedic Trauma Association classification system (AO/OTA); type of nail; cervical-diaphyseal angle; surgical wait times; anti-osteoporotic medication; complete post-operative weight bearing; and radiological parameters (namely the lag-screw position with respect to the femoral head, the Cleveland system, the tip-apex distance (TAD), and the calcar-referenced tip-apex distance (CalTAD)). Results The incidence of cut-out across the sample was 5.6%, with a higher incidence in female patients. A significantly higher risk of this complication was correlated with lag-screw tip positioning in the upper part of the femoral head in the anteroposterior radiological view, posterior in the latero-lateral radiological view, and in the Cleveland peripheral zones. The tip-apex distance and the calcar-referenced tip-apex distance were found to be highly significant predictors of the risk of cut-out at cut-offs of 30.7 mm and 37.3 mm, respectively, but the former appeared more reliable than the latter in predicting the occurrence of this complication. Conclusion The tip-apex distance remains the most accurate predictor of cut-out, which is significantly greater above a cut-off of 30.7 mm. Cite this article: G. Caruso, M. Bonomo, G. Valpiani, G. Salvatori, A. Gildone, V. Lorusso, L. Massari. A six-year retrospective analysis of cut-out risk predictors in cephalomedullary nailing for pertrochanteric fractures: Can the tip-apex distance (TAD) still be considered the best parameter?. Bone Joint Res 2017;6:481–488. DOI: 10.1302/2046-3758.68.BJR-2016-0299.R1.
Collapse
Affiliation(s)
- G Caruso
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Borsari 47, 44121 Ferrara FE, Italy
| | - M Bonomo
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Borsari 47, 44121 Ferrara FE, Italy
| | - G Valpiani
- Research and Innovation Office, Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna, Via Aldo Moro 8, 44124, Cona, Ferrara FE, Italy
| | - G Salvatori
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Borsari 47, 44121 Ferrara FE, Italy
| | - A Gildone
- Orthopaedic and Traumatology Department, Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna, Via Aldo Moro 8, 44124, Cona, Ferrara FE, Italy
| | - V Lorusso
- Orthopaedic and Traumatology Department, Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna, Via Aldo Moro 8, 44124, Cona, Ferrara FE, Italy
| | - L Massari
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Borsari 47, 44121 Ferrara FE, Italy
| |
Collapse
|
24
|
Silvestris N, Brunetti O, Marchetti P, Mazzuca F, Vasile E, Gelsomino F, Zanon S, Giardini Casadei A, Milella M, Basile D, Barni S, Scartozzi M, Laffi A, Delfanti S, Cella C, De Vita F, Giusi G, Lorusso V, Scarpa A, Cascinu S. Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Forcignanò R, Petrucelli L, Cazzaniga ME, Lupo LI, Chiuri VE, Cairo G, De Matteis E, Febbraro A, Giordano G, Campidoglio S, Fabi A, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Scavelli C, Romito S, Cusmai A, Palmiotti G, Tornesello A, Ciccarese M. Abstract P4-13-15: Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experience. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Everolimus, an mTOR inhibitor, in combination with exemestane is approved for hormone receptor (HR) positive advanced breast cancer (ABC), after failure of treatment with non-steroidal aromatase inhibitor (NSAI). We assessed the toxicity of the combination and the correlation between dose intensity and response to therapy, in a real world population of ABC from 11 Italian centers. Moreover, we evaluated OS of the whole population, RR and PFS according to line of treatment (from 1rd to 3th and from 4th on).
METHODS: 154 pts were treated with combination of everolimus 10 mg and exemestane 25 mg daily from 05/2011 today. Median age was 62 (47-82). Median time to metastatic disease was 49 months (0-269). Median number of metastatic sites was 2 (55.2% of pts visceral versus 44.8% non visceral disease). N=117 (75.9%) pretreated with HT as adjuvant; N=126 pts (81.8%) treated with HT for advanced disease prior to EVE/EXE, with a median of one line (0-5). N=102 pts (66.2%) treated with chemotherapy for metastatic disease, with a median of one line (0-6) before everolimus treatment.
RESULTS: Sixteen pts received EVE/EXE as 1st line (10.4%), 39 as 2nd (25.3%), 37 as 3rd (24%), 62 as 4th or more (40,3%). Response was evaluable in 127 out of 154 pts; CR/PR/SD respectively 5/27/56 pts. RR according to line (from 1st to 3rd vs ≥ 4th) was respectively 22.8% vs 26.4% (p=0,864). The median PFS for all population (150 pts) was 38 weeks (95% CI: 33-42). The PFS according to line (1st- 3rd vs ≥ 4th) was 38 wks in both subgroups, p=0.73. OS (126/154 pts) was 28 mths (95% CI: 31-38). The most frequent adverse events were collected in the table.
Adverse eventsOverall %Grade 3-4 %Stomatitis55.810.4Hypercholesterolemia47.40.0Asthenia42.95.2Hyperglycemia36.45.8Hypertriglyceridemia29.20.6Anemia28.63.9Peripheral edema24.71.3Rash23.40.6Increased ALT/AST/GGT21.46.5Thrombocytopenia19.53.9Diarrhea18.81.9Weight loss18.21.3Dysgeusia17.50.6Pneumonitis15.61.9Cutaneous toxicity14.90.6Infection14.33.2Neutropenia11.71.9Nausea11.70.0Anorexia (without stomatitis)10.41.3Electrolyte alterations9.71.3Urea/creatinine increase6.51.3Vomiting6.50.0Uric acid increase4.50.0
Median duration of treatment with everolimus 10 mg and 5 mg was respectively 180 (9-854) and 129 days (3-738). Fifty-eight pts (37,6%) never stopped treatment with everolimus 10 mg; 16 pts (10,4%) definitively stopped everolimus for toxicity; 80 pts (52,0%) temporarily interrupted the treatment, resuming at dose level 10 mg (31 pts) or reducing at 5 mg (49 pts). Main reason for discontinuation/interruption was stomatitis G2-G3. RR and PFS evaluated according to dose intensity, 10 mg vs 5 mg, were respectively 25.9% vs 30% p=0.779, 38 wks (27-44) vs 40 wks (31-48) P=0.614
CONCLUSIONS: efficacy in terms of RR and PFS of the combination EVE/EXE is not related to dose intensity (10 mg vs 5 mg), the discontinuation of the treatment is high with the starting dose of 10 mg, the toxicity is consistent with previous phase II-III studies although we collected some different toxicities.
Citation Format: Forcignanò R, Petrucelli L, Cazzaniga ME, Lupo LI, Chiuri VE, Cairo G, De Matteis E, Febbraro A, Giordano G, Campidoglio S, Fabi A, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Scavelli C, Romito S, Cusmai A, Palmiotti G, Tornesello A, Ciccarese M. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experience. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-15.
Collapse
Affiliation(s)
- R Forcignanò
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - L Petrucelli
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - ME Cazzaniga
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - LI Lupo
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - VE Chiuri
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - G Cairo
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - E De Matteis
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - A Febbraro
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - G Giordano
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - S Campidoglio
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - A Fabi
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - M Giampaglia
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - D Bilancia
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - N La Verde
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - E Maiello
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - M Morritti
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - F Giotta
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - V Lorusso
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - C Scavelli
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - S Romito
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - A Cusmai
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - G Palmiotti
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - A Tornesello
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| | - M Ciccarese
- "Vito Fazzi" Hospital, Lecce, Italy; "AO San Gerardo", Monza, Italy; "Sacro Cuore di Gesù Fatebenefratelli" Hospital, Benevento, Italy; "Regina Elena" National Cancer Institute, Roma, Italy; "San Carlo" Hospital, Potenza, Italy; "AO Fatebenefratelli e Oftalmico", Milano, Italy; "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (Foggia), Italy; "Giovanni Paolo II" Institute, Bari, Italy; "S. Cuore di Gesù" Hospital, Gallipoli (Lecce), Italy; "Ospedali Riuniti" Hospital, Foggia, Italy; "Di Venere" Hospital, Bari, Italy
| |
Collapse
|
26
|
Zolfino T, Lorusso V, D'Angelo S, Sansonno D, Giannitrapani L, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S, Gasbarrini A, Pirisi M, Cillo U, Picciotto A, Villa E, Giovanis P, Pinotti G, Saitta C, Erminero C, de Giorgio M, Daniele B. Hepatocellular Carcinoma In Elderly Patients: final results of The Italian Cohort Of GIDEON (Global Investigational of therapeutic DEcisions in HCC and of its treatment with sorafeNib) Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
D'Angelo S, Germano D, Zolfino T, Sansonno D, Montalto G, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S, Gasbarrini A, Pirisi M, Cillo U, Marenco S, Villa E, Giovanis P, Pinotti G, Saitta C, Erminero C, de Giorgio M, Lorusso V. Final results of the gideon study according to patient etiology: The italian experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Massari L, Osti R, Lorusso V, Setti S, Caruso G. Biophysical stimulation and the periprosthetic bone: is there a rationale in the use of Pulsed Electromagnetic Fields after a hip or knee implant? J BIOL REG HOMEOS AG 2015; 29:1013-1015. [PMID: 26753669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The biophysical stimulation of bone and cartilage, using Pulsed ElectroMagnetic Fields (PEMF), covers many different aspects of bone formation and/or cartilage repair, such as healing of delayed or non-union of fracture, bone necrosis, osteocartilagineous defects. To date there are no specific data on the effects of PEMFs in osteointegration of prosthetic implants but there are some papers that denote clinical advantages, in terms of early recovery, in patients treated with these procedures. Considering these clinical applications, PEMF stimulation around hip or knee joint implants could be useful to reduce the bone oedema, pain and to reduce excessive bone reabsorption around the femoral stems.
Collapse
Affiliation(s)
- L Massari
- Orthopaedic Institute of University, Ferrara, Italy
| | - R Osti
- Orthopaedic Institute of University, Ferrara, Italy
| | - V Lorusso
- Orthopaedic Institute of University, Ferrara, Italy
| | - S Setti
- IGEA Spa, RandD Department, Carpi (MO), Italy
| | - G Caruso
- Orthopaedic Institute of University, Ferrara, Italy
| |
Collapse
|
29
|
De Summa S, Pinto R, Strippoli S, Natalicchio I, Azzariti A, Cramarossa A, Signorile M, Albano A, Lorusso V, Guida G, Guida M, Tommasi S. Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv337.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Brunetti O, Porcelli L, Graziano G, Lorusso V, Signorile M, Delcuratolo S, Palermo L, Massiah G, Azzariti A, Silvestris N. Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Latorre A, Caldarola L, Petroni S, Giotta F, Lorusso V, Trotti I, Simone G. 1899 Correlation between Ki-67 and FISH testing of HER2 IHC 1+ early invasive breast cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30848-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Zolfino T, Lorusso V, D'Angelo S, Sansonno D, Giannitrapani L, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S, Gasbarrini A, Pirisi M, Cillo U, Picciotto A, Villa E, Giovanis P, Pinotti G, Raimondo G, Erminero C, De Giorgio M, Daniele B. P-110 Hepatocellular carcinoma in elderly patients: Final results of the Italian cohort of GIDEON study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 2015; 26:1201-1207. [PMID: 25735317 DOI: 10.1093/annonc/mdv130] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Accepted: 02/20/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We report the results from a first-line phase III randomized clinical trial on metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding bevacizumab (B) to standard first-line chemotherapy (CT). PATIENTS AND METHODS mCRC patients were randomized to receive first-line CT (FOLFIRI or FOLFOX4) plus B (arm A) or CT only (arm B). The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), response rate (ORR) and safety. Three hundred and fifty patients and 310 events were required to have an 80% statistical power to detect a difference in PFS between the groups. RESULTS Between November 2007 and March 2012, 376 patients were randomized. About 60% of patients received FOLFOX4 and 40% FOLFIRI. After a median follow-up of 36 months, 343 progressions and 275 deaths had been observed in the overall population. The median PFS was 9.6 [95% confidence interval (CI) 8.2-10.3] and 8.4 (95% CI 7.2-9.0) months for arms A and B, respectively, with a hazard ratio of 0.86 (95% CI 0.70-1.07; P = 0.182). No statistically significant differences in OS or ORR were observed. B-containing regimens were associated with more frequent hypertension, bleeding, proteinuria and asthenia. CONCLUSIONS The addition of B to standard first-line CT for mCRC did not provide a benefit in terms of PFS, OS or ORR. Further research is warranted to better identify the target population. CLINICAL TRIAL NUMBER NCT01878422.
Collapse
Affiliation(s)
- A Passardi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori.
| | - O Nanni
- Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola
| | - D Tassinari
- Department of Oncology, Per gli Infermi Hospital, Rimini
| | - D Turci
- Oncology Unit, S. Maria delle Croci Hospital, Ravenna
| | - L Cavanna
- Medical Oncology Unit, Guglielmo da Saliceto Hospital, Piacenza
| | - A Fontana
- Oncology Unit, University Hospital of Modena and Reggio Emilia, Modena
| | - S Ruscelli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
| | - C Mucciarini
- Medical Oncology Unit, Ramazzini Hospital, Carpi
| | - V Lorusso
- Medical Oncology Unit, Vito Fazzi Hospital, Lecce; Department of Medical Oncology, Istituto Tumori, Bari, Italy
| | - A Ragazzini
- Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola
| | - G L Frassineti
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
| | - D Amadori
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
| |
Collapse
|
34
|
Passardi A, Scarpi E, Fontana A, Cavanna L, Ruscelli S, Turci D, Lorusso V, Mucciarini C, Tassinari D, Ragazzini A, Valgiusti M, Ulivi P, Frassineti G, Amadori D. P-283 Impact of second-line cetuximab-containing therapy in patients with KRAS wild type metastatic colorectal cancer: results from ITACa trial. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
D'Angelo S, Germano D, Zolfino T, Sansonno D, Montalto G, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S, Gasbarrini A, Pirisi M, Cillo U, Marenco S, Villa E, Giovanis P, Pinotti G, Raimondo G, Erminero C, De Giorgio M, Lorusso V. P-111 Final results of the GIDEON (Global Investigational of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study according to patient etiology: The Italian experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Chaabane L, Tei L, Miragoli L, Lattuada L, von Wronski M, Uggeri F, Lorusso V, Aime S. In Vivo MR Imaging of Fibrin in a Neuroblastoma Tumor Model by Means of a Targeting Gd-Containing Peptide. Mol Imaging Biol 2015; 17:819-28. [DOI: 10.1007/s11307-015-0846-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
37
|
Laudadio V, Lorusso V, Lastella N, Dhama K, Karthik K, Tiwari R, Alam GM, Tufarelli V. Enhancement of Nutraceutical Value of Table Eggs Through Poultry Feeding Strategies. INT J PHARMACOL 2015. [DOI: 10.3923/ijp.2015.201.212] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015; 88:20140526. [PMID: 25651409 PMCID: PMC4651256 DOI: 10.1259/bjr.20140526] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Objective: To determine whether increased elimination of gadobenate ion via the hepatobiliary pathway might compensate for reduced/absent elimination via the urinary pathway in the event of compromised renal function, as a possible protective mechanism against nephrogenic systemic fibrosis (NSF). Methods: 15 male Crl:CD® R(SD)Br rats (Charles River Italia, Como, Italy) randomized to three treatment groups: (1) animals with occluded bile ducts, (2) animals with occluded renal vessels and (3) control animals, each received 0.25 mmol kg−1 of bodyweight of gadobenate dimeglumine (MultiHance®; Bracco Imaging SpA, Milan, Italy). Urine and bile were collected from 0−30, 30−60, 60−120, 120−240 and 240−480 min after gadobenate dimeglumine administration prior to exsanguination. Determinations of gadobenate ion in blood, bile and urine were performed by high-performance liquid chromatography. Gadolinium (Gd3+) levels in excised liver and kidneys were determined by X-ray fluorescence. Results: The recovery of gadobenate ion in the urine of rats with bile duct occlusion was significantly higher than that in the urine of normal rats (89.1 ± 4.2% vs 60.6 ± 2.8%; p < 0.0001). Conversely, mean recovery in the bile of rats with renal vessel occlusion was significantly higher than that in the bile of normal rats (96.16 ± 0.55% vs 33.5 ± 4.7%; p < 0.0001). Gadobenate ion was not quantifiable in any group 8 h post-injection. Conclusion: Compensatory elimination may be an effective means to overcome compromised renal or hepatobiliary elimination. Advances in knowledge: The absence of NSF in at-risk patients administered with gadobenate dimeglumine may in part reflect greater Gd3+ elimination via the hepatobiliary route.
Collapse
Affiliation(s)
- M A Kirchin
- 1 Global Medical and Regulatory Affairs, Bracco Imaging SpA, Milan, Italy
| | | | | |
Collapse
|
39
|
Ciccarese M, Orlando L, Fedele P, Schiavone P, Maiello E, Cilenti P, Aieta M, Bozza G, Forcignanò M, Febbraro A, Bordonaro R, Romito S, Rinaldi A, Borsellino N, Riccardi F, Pisconti S, Lorusso V, Colucci G, Cinieri S. A Multicenter Phase Ii Trial of Nab-Paclitaxel in Combination with Capecitabine in Patients (Pts) with Her-2 Negative and Triple Negative Advanced Breast Cancer (Abc): an Interim Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Passardi A, Farolfi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Amadori D. Impact of Pre-Treatment Lactate Dehydrogenase (Ldh) Levels on Prognosis and Bevacizumab Efficacy in Advanced Colorectal Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Giotta F, Petroni S, Caldarola L, Latorre A, Mallamaci R, Lorusso V, Zambetti M, Simone G. Fish Testing of Her2 Ihc 1+ Early Breast Cancer with Unfavorable Prognostic Factors. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Lorusso V, Śmiałowska-Janiszewska A, Krzemieniecki K, Novoa SA, Mefti F, Janssen J, Steger G, Bird B, Turazza M, Yosef H, Albuisson E, Barnadas A, Batist G, De Mouzon J, Erdkamp F, Leonard R, Namer M, Maumus-Robert S, Aapro M. Use of Liposomal Doxorubicin for Metastatic Breast Cancer Management Across Europe: Results of Eos (European Observatory & Survey). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Lorusso V, Giotta F, Bordonaro R, Maiello E, Del Prete S, Gebbia V, Filippelli G, Pisconti S, Cinieri S, Romito S, Riccardi F, Forcignanò R, Ciccarese M, Petrucelli L, Saracino V, Lupo LI, Gambino A, Leo S, Colucci G. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study. Int J Oncol 2014; 45:2137-42. [PMID: 25176223 DOI: 10.3892/ijo.2014.2604] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Accepted: 06/20/2014] [Indexed: 11/05/2022] Open
Abstract
We conducted a phase III multicenter randomized trial to compare the efficacy of the combination of liposome encapsulated doxorubicin (Myocet(©)) plus either cyclophosphamide (MC) or vinorelbine (MV). Since July 2006, 233 patients affected with metastatic breast cancer were randomized to receive the combination of Myocet (M) 60 mg/m(2) i.v. plus cyclophosphamide (C) 600 mg/m2 on Day 1 of a 21‑day cycle (Arm A) or Myocet (M) at 50 mg/m2 plus vinorelbine (V) 25 mg/m2 i.v. on Day 1 and V 60 mg/m2 orally on Day 8 on a 21‑day cycle (Arm B). The primary endpoints of the study was time to progression (TTP); secondary endpoints were RR, toxicity and OS. Response was observed in 53/116 (45.7%) evaluable patients of Arm A vs. 51/112 (45.5%) of Arm B, respectively (P=NS). Median TTP was 41 weeks (95% CI, 32‑51) and 34 weeks (95% CI, 26‑39), for M/C and M/V, respectively (P=0.0234). The difference in median OS was not statistically significant (131 vs. 122 weeks; P=0.107). With regard to toxicity, patients treated with MV showed a slight increase of neutropenia and constipation, as compared to those treated with MC. No clinical signs of cardiotoxicity were observed. The MC combination remains as an unbeaten 'standard' in first line treatment of MBC.
Collapse
Affiliation(s)
- V Lorusso
- National Cancer Research Center, Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - F Giotta
- National Cancer Research Center, Istituto Tumori Giovanni Paolo II, Bari, Italy
| | | | - E Maiello
- Casa Sollievo della Sofferenza Hospital IRCCS, San Giovanni Rotondo (FG), Italy
| | - S Del Prete
- Frattamaggiore Hospital, Frattamaggiore (NA), Italy
| | - V Gebbia
- La Maddalena Hospital, Palermo, Italy
| | | | | | - S Cinieri
- Brindisi Medical Oncology Department and Breast Unit e Medical Department, European Insitute of Oncology, Milan, Italy
| | - S Romito
- Ospedali Riuniti Hospital, Foggia, Italy
| | | | | | | | | | | | - L I Lupo
- Vito Fazzi Hospital, Lecce, Italy
| | | | - S Leo
- Vito Fazzi Hospital, Lecce, Italy
| | | | | |
Collapse
|
44
|
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25:1328-1333. [PMID: 24603643 PMCID: PMC4071754 DOI: 10.1093/annonc/mdu101] [Citation(s) in RCA: 178] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Accepted: 02/25/2014] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of chemotherapy-induced nausea and vomiting (CINV). NEPA is a new oral fixed-dose combination of 300 mg netupitant, a highly selective NK1 receptor antagonist (RA) and 0.50 mg palonosetron (PALO), a pharmacologically and clinically distinct 5-HT3 RA, which targets dual antiemetic pathways. PATIENTS AND METHODS This multinational, randomized, double-blind, parallel group phase III study (NCT01339260) in 1455 chemotherapy-naïve patients receiving moderately emetogenic (anthracycline-cyclophosphamide) chemotherapy evaluated the efficacy and safety of a single oral dose of NEPA versus a single oral dose (0.50 mg) of PALO. All patients also received oral dexamethasone (DEX) on day 1 only (12 mg in the NEPA arm and 20 mg in the PALO arm). The primary efficacy end point was complete response (CR: no emesis, no rescue medication) during the delayed (25-120 h) phase in cycle 1. RESULTS The percentage of patients with CR during the delayed phase was significantly higher in the NEPA group compared with the PALO group (76.9% versus 69.5%; P = 0.001), as were the percentages in the overall (0-120 h) (74.3% versus 66.6%; P = 0.001) and acute (0-24 h) (88.4% versus 85.0%; P = 0.047) phases. NEPA was also superior to PALO during the delayed and overall phases for all secondary efficacy end points of no emesis, no significant nausea and complete protection (CR plus no significant nausea). NEPA was well tolerated with a similar safety profile as PALO. CONCLUSIONS NEPA plus a single dose of DEX was superior to PALO plus DEX in preventing CINV following moderately emetogenic chemotherapy in acute, delayed and overall phases of observation. As a fixed-dose antiemetic drug combination, NEPA along with a single dose of DEX on day 1 offers guideline-based prophylaxis with a convenient, single-day treatment.
Collapse
Affiliation(s)
- M Aapro
- Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
| | - H Rugo
- Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA
| | - G Rossi
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - G Rizzi
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - M E Borroni
- Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland
| | - I Bondarenko
- Department of Oncology, Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine
| | | | | | - S Cardona-Huerta
- Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey, Mexico
| | - V Lorusso
- National Cancer Institute Giovanni Paolo II, Bari, Italy
| | - M Karthaus
- Department of Hematology, Oncology and Palliative Medicine, Staedt. Klinikum Neuperlach and Harlaching, München, Germany
| | | | - S Grunberg
- Fletcher Allen Health Care, Burlington, USA
| |
Collapse
|
45
|
Rugo HS, Rossi G, Rizzi G, Borroni ME, Lorusso V, Karthaus M, Bondarenko I, Sarosiek TJ, Aapro MS. Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Breast cancer (BC) patients receiving anthracycline-cyclophosphamide (AC) chemotherapy (CT) are at risk for developing CINV due not only to the emetogenicity of the CT but also to young age and gender. As recommended by international antiemetic guidelines, targeting multiple molecular pathways involved in emesis related to AC is important for maximizing control of CINV and improving the functional status of BC patients during CT. NEPA is a fixed-dose combination of netupitant (NETU), a highly-selective NK1 receptor antagonist (RA), and palonosetron (PALO), a pharmacologically distinct 5-HT3 RA, that targets dual antiemetic pathways with a convenient single day dose.
Methods:
This was a multinational, randomized, double-blind, phase 3 study evaluating the efficacy and safety of a single oral dose of NEPA (NETU 300 mg + PALO 0.50 mg) versus a single oral 0.50 mg dose of PALO in chemotherapy-naïve patients receiving AC. All patients received oral dexamethasone (DEX) on day 1 (12 mg NEPA arm; 20 mg PALO arm). The primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) in the delayed phase, 25-120h after CT. The Functional Living Index-Emesis (FLIE) questionnaire with a 5-day recall period was used to assess the impact of CINV on patients’ daily lives as a secondary endpoint. The FLIE consists of 9 nausea-specific (nausea domain) and 9 vomiting-specific (vomiting domain) items that address the effect of nausea and vomiting on daily life. Each item is scored on a 7-point 100 mm visual analog scale with anchors of “none/not at all” and “a great deal”. The proportion of patients with an average item score >6 reflecting “no impact on daily life” (NIDL) (ie, total FLIE score >108, nausea/vomiting domain score >54) was compared for NEPA vs PALO using a Cochran-Maentel-Haenszel test stratified by age class and region.
Results:
1455 patients with a mean age of 54 were randomized to receive NEPA or PALO. Treatment groups were similar; 98% were females with BC (97%).
As previously reported (ASCO 2013), NEPA showed superior CR rates compared to PALO for the acute 0-24h (88% vs 85%; p = 0.047), delayed (77% vs 70%; p = 0.001) and overall 0-120h (74% vs 67%; p = 0.001) phases.
A greater proportion of NEPA-treated patients reported NIDL for nausea, vomiting and combined domains compared to PALO.
% Patients with NIDL (Overall 0-120h)NEPA (N = 724)PALO (N = 725)p-valueNausea domain72%66%0.015Vomiting domain90%84%0.001Overall combined79%72%0.0056 patients excluded who did not receive AC or study drug
The adverse event (AE) profile was comparable between groups. Most frequently reported treatment-related AEs for NEPA and PALO, respectively, were headache (3.3%, 3.0%) and constipation (2.1%, 2.1%).
Conclusions:
In this large Phase 3 study of predominantly females with BC receiving AC, NEPA was superior to PALO in preventing CINV and reducing the negative impact of CINV on patients’ daily lives. As a fixed-dose antiemetic drug combination including an NK1 RA and 5-HT3 RA, NEPA offers improved efficacy over PALO alone, with a convenient single-day dose, and oral DEX only on day 1.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-01.
Collapse
Affiliation(s)
- HS Rugo
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - G Rossi
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - G Rizzi
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - ME Borroni
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - V Lorusso
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - M Karthaus
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - I Bondarenko
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - TJ Sarosiek
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - MS Aapro
- University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Helsinn Healthcare SA, Lugano, Switzerland; National Cancer Institute Giovanni Paolo II, Bari, Italy; Hematology & Oncology, Staedt. Klinikum Neuperlach and Harlaching, Munich, Germany; Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine; NZOZ Magodent, Warsaw, Poland; Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| |
Collapse
|
46
|
Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, Passalacqua R, Iaffaioli V, Zilembo N, Mencoboni M, Roselli M, Pappagallo G, Pronzato P. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol 2013; 31:797. [PMID: 24307348 DOI: 10.1007/s12032-013-0797-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 11/27/2013] [Indexed: 12/13/2022]
Abstract
Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥ 20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 10(9)/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.
Collapse
Affiliation(s)
- S Barni
- Oncology Department, Azienda Ospedaliera Treviglio, Treviglio, BG, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Despite the fact that the hepatocellular carcinoma (HCC) represents a major health problem, very few interventions are available for this disease, and only sorafenib is approved for the treatment of advanced disease. Of note, only very few interventions have been thoroughly evaluated over time for HCC patients compared with several hundreds in other, equally highly lethal, tumours. Additionally, clinical trials in HCC have often been questioned for poor design and methodological issues. As a consequence, a gap between what is measured in clinical trials and what clinicians have to face in daily practice often occurs. As a result of this scenario, even the most recent guidelines for treatment of HCC patients use low strength evidence to make recommendations. In this review, we will discuss some of the potential methodological issues hindering a rational development of new treatments for HCC patients.
Collapse
Affiliation(s)
- G Daniele
- Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy.
| | | | | | | | | | | |
Collapse
|
48
|
Romito F, Cormio C, De Padova S, Lorusso V, Berio MA, Fimiani F, Piattelli A, Palazzo S, Abram G, Dudine L, Guglielmi A, Galise I, Romito S, Mattioli V. Patients attitudes towards sleep disturbances during chemotherapy. Eur J Cancer Care (Engl) 2013; 23:385-93. [PMID: 23947497 DOI: 10.1111/ecc.12106] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2013] [Indexed: 11/27/2022]
Abstract
Sleep disturbances are among the most distressing symptoms in cancer: they often co-occur with fatigue, pain and psychological distress. Despite the negative impact on quality of life, patients rarely seek help for managing their sleep disturbances. This paper presents the results of a multicentre observational study on patients' attitudes towards their sleep problems. The study also investigates symptom correlates. Patients responded to a semi-structured interview and completed the following questionnaires: Pittsburgh Sleep Quality Index; Brief Fatigue Inventory; Hospital Anxiety and Depression Scale; and European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life QLQ-C30 Questionnaire (QLQ-C30). Four hundred and three cancer patients were enrolled in the study. Bad sleepers constituted 66% of the sample. Thirty-eight per cent of them had not turned to any professional to solve their sleep disturbances because they had various beliefs about the importance of the problem and the possibility to be treated. The main correlates of sleep disturbances were psychological distress, reduced physical functioning and reduced overall quality of life. In conclusion, there is a need to sensitise patients to actively search for a solution to their sleep disturbances so they can be solved along with other co-occurring symptoms. Doctors could also be encouraged to dedicate more attention to routinely asking cancer patients about eventual sleep disturbances.
Collapse
Affiliation(s)
- F Romito
- Experimental Unit of Psycho-Oncology, Department of Critical Area and Surgery, National Cancer Research Center, Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Silvestris N, Piscitelli D, Crucitta E, Fiore M, De Lena M, Lorusso V. Unusual Response to Second-Line Single-Agent Gemcitabine in Locally Advanced Primary Leiomyosarcoma of the Lung: A Case Report. J Chemother 2013; 15:507-9. [PMID: 14603882 DOI: 10.1179/joc.2003.15.5.507] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Primary leiomyosarcomas (LMSs) of the lung are extremely rare malignancies that have been the subject of single or small series of case reports. Today, the gold standard of treatment in patients with locally advanced and metastatic disease includes one of the many possible regimens containing an anthracycline and/or ifosfamide. Few chemotherapy agents are active in the second-line setting. In particular, gemcitabine is considered quite ineffective in the treatment of first- as well as second-line chemotherapy of soft tissue sarcoma and responses to this agent are seldom reported. In this paper, we report a single patient with primary LMS of the lung previously treated with a combination of epirubicin and ifosfamide. The patient responded to second-line chemotherapy with gemcitabine 1250 mg/m2 given as a 30-minute infusion on days 1, 8, and 15 of a 28-day cycle and showed an 8-month response duration and negligible toxicity. Gemcitabine may represent an alternative to the best supportive care in patients affected with soft tissue sarcoma who fail first-line chemotherapy.
Collapse
Affiliation(s)
- N Silvestris
- Operative Unit of Medical Oncology, Oncology Institute of Bari, Italy
| | | | | | | | | | | |
Collapse
|
50
|
Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ 2013; 16:691-700. [PMID: 23441975 DOI: 10.3111/13696998.2013.779921] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Patients with bone metastases often experience skeletal-related events (SREs: radiation or surgery to bone, pathologic fracture, and spinal cord compression). This study examined health resource utilization and costs associated with SREs. METHODS Data presented are from the European cohort (Germany, Italy, Spain, and the UK) of patients with solid tumours enrolled in a multi-national, prospective, observational study in patients with solid tumours or multiple myeloma. Patients with Eastern Cooperative Oncology Group score 0-2 and life expectancy ≥6 months, who experienced an SRE up to 97 days before enrolment, were eligible. Health resource utilization associated with SREs (including number/length of inpatient stays, numbers of procedures and outpatient visits) were collected through chart review for up to 97 days before enrolment and prospectively during follow-up. Country-specific cost calculations were performed. RESULTS In total, 478 eligible patients contributed 893 SREs to this analysis. Radiation to bone occurred most frequently (66% of total). Spinal cord compression (7%) and surgery to bone (10%) were the least common events, but most likely to require inpatient stays. The most costly SREs were also spinal cord compression (mean per SRE across countries, €4884-€12,082) and surgery to bone (€3348-€9407). Inpatient stays were the main cost drivers. LIMITATIONS Health resource utilization used to calculate the costs associated with SREs may have been under-estimated as a result of exclusion of patients with low performance status or life expectancy; unavailable information and exclusion of resource consumption associated with pain. Thus, the estimate of associated costs is likely to be conservative. CONCLUSIONS SREs result in considerable health resource utilization, imposing a substantial financial burden driven by inpatient stays. Treatments that prevent/delay SREs may help ease this burden, thereby providing cost savings across European healthcare systems.
Collapse
Affiliation(s)
- G Hechmati
- Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|